Hematide

PALO ALTO, Calif., Aug 31, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the company's participation in the following investor conferences during the month of September. - Morgan Stanle...

PALO ALTO, Calif. & OSAKA, Aug 05, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide(TM)/peginesatide, for the treatment of anemia in chronic r...

PALO ALTO, Calif., Aug 04, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payment...

PALO ALTO, Calif., Jul 27, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Paul Cleveland, the company's chief financial officer and executive vice president, Corporate Development, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at ...

PALO ALTO, Calif., Jul 20, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the completion of the sale at par value of all auction rate securities (ARS) held by UBS AG and its affiliates (UBS) in a transaction which generated net proceeds of $5.0 million to Affymax, after payment of $5.4 million from the p...

PALO ALTO, Calif., Jun 22, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that it has received $30 million in development milestone payments from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide(TM)/peginesatide, Affymax's investigat...

PALO ALTO, Calif. & DEERFIELD, Ill. & OSAKA, Japan, Jun 21, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE, 4502), today announced preliminary top-line results from the Phase 3 clinical program ...

PALO ALTO, Calif., Jun 20, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that its management team will host a conference call and webcast tomorrow, Monday, June 21, 2010 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). Conference Call Details To access the live conference call tomorrow, Monday, June 21, 2...

PALO ALTO, Calif., May 06, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2010. The net loss for the first quarter of 2010 was $7.9 million compared to a net loss of $21.7 million for the first quarter of 2009. Affymax recognized revenue for the qu...

PALO ALTO, Calif., Apr 22, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PE...

ORLANDO, Fla., Apr 15, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The dat...

PALO ALTO, Calif., Apr 12, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that John A. Orwin, an executive with over 20 years of experience in the biotechnology and pharmaceutical industries, has joined the company as president and chief operating officer. In this newly created position which will repor...

PALO ALTO, Calif., Mar 31, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Sylvia Wheeler to vice president, Corporate Communications. Ms. Wheeler has more than 20 years of corporate communications and investor relations experience in the bioscience industry and is a member of the board ...

PALO ALTO, Calif., & DEERFIELD, Ill., Mar 30, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide(TM)/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring ...

PALO ALTO, Calif., Mar 16, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Jeffrey Knapp, the company's chief commercial officer, will present at the Barclays 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 2:00 p.m. ET (11:00 a.m. PT). A live webcast of the presentation will be ava...

PALO ALTO, Calif., Mar 10, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide(TM), Affymax's investigational drug for ...

PALO ALTO, Calif., Mar 04, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the year ended December 31, 2009. The net loss for the year 2009 was $76.5 million compared to a net loss of $86.5 million for the year ended December 31, 2008. Affymax recognized revenue for the year ended De...

PALO ALTO, Calif., Mar 03, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the 30th Annual Cowen and Company Health Care Conference on Tuesday, March 9, 2010 at 1:30 p.m. ET (10:30 a.m. PT). A live webcast of the pr...

PALO ALTO, Calif., Feb 24, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Jeffrey Knapp, the company's chief commercial officer, will participate in a panel discussion at the RBC Capital Markets Healthcare Conference on Wednesday, March 3, 2010 at 9 a.m. EST in New York. A live webcast of the prese...

PALO ALTO, Calif., Feb 01, 2010 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the 12TH Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 4:00 p.m. ET (1:00 p.m. PT). A live webcast of the presentation...